🔗 Share this article US and UK Finalize Zero-Tariff Accord on Prescription Drugs. Representative image of medicine trade. The UK and US have announced a important trade agreement that will maintain zero levies on British pharmaceutical products going into the American market. Key Provisions of the Deal In exchange for the tariff guarantee, the UK has pledged to raise spending on medicines through the public health system. This commitment ensures that import taxes on these key goods will stay at zero for a duration of the next three years. This agreement is in response to earlier statements to hike import taxes on branded pharmaceutical products, with potential rates floated reaching one hundred percent. "This deal between the UK strengthens the global environment for new treatments and brings long-overdue equity to transatlantic drug exports," an announcement noted. Commercial Importance Pharmaceuticals are one of the Britain's largest export categories to the US, which is easily the primary destination for major UK drugmakers. Export figures show that in the 12 months prior to last September, the UK shipped medicines totaling £11.1bn to the US. This figure accounted for a significant portion of total UK exports in that period. "This agreement protects jobs, boosts funding and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a minister commented. Key NHS Changes The pact includes several key commitments from the British government: Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new treatments to be unaffordable by twenty-five percent. Higher Drug Budget: There is a target to double overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period. Refund Ceiling: The sum manufacturers must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds were more than twenty percent. Recent Tensions The deal comes amid a long-running row between the sector and the British authorities over spending levels and approval rates. These tensions were heightened by arguments that US consumers were charged several times more for the equivalent treatments than consumers in the Britain and the EU. Over the last 18 months, several significant manufacturing plans in the UK have been paused or abandoned, while substantial expansions have been directed toward American operations. A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
Representative image of medicine trade. The UK and US have announced a important trade agreement that will maintain zero levies on British pharmaceutical products going into the American market. Key Provisions of the Deal In exchange for the tariff guarantee, the UK has pledged to raise spending on medicines through the public health system. This commitment ensures that import taxes on these key goods will stay at zero for a duration of the next three years. This agreement is in response to earlier statements to hike import taxes on branded pharmaceutical products, with potential rates floated reaching one hundred percent. "This deal between the UK strengthens the global environment for new treatments and brings long-overdue equity to transatlantic drug exports," an announcement noted. Commercial Importance Pharmaceuticals are one of the Britain's largest export categories to the US, which is easily the primary destination for major UK drugmakers. Export figures show that in the 12 months prior to last September, the UK shipped medicines totaling £11.1bn to the US. This figure accounted for a significant portion of total UK exports in that period. "This agreement protects jobs, boosts funding and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a minister commented. Key NHS Changes The pact includes several key commitments from the British government: Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new treatments to be unaffordable by twenty-five percent. Higher Drug Budget: There is a target to double overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period. Refund Ceiling: The sum manufacturers must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds were more than twenty percent. Recent Tensions The deal comes amid a long-running row between the sector and the British authorities over spending levels and approval rates. These tensions were heightened by arguments that US consumers were charged several times more for the equivalent treatments than consumers in the Britain and the EU. Over the last 18 months, several significant manufacturing plans in the UK have been paused or abandoned, while substantial expansions have been directed toward American operations. A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had decreased as a proportion of its overall budget over the previous ten-year period.